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Background: The Svelte (New Providence, NJ) drug-eluting stent (DES) combines
sirolimus with a novel, amino acid-based (PEA) bioabsorbable drug carrier. The stent
is mounted on an Integrated Delivery System (IDS) consisting of a low compliant
balloon with balloon control bands (BCBs) enveloping the balloon edges and afﬁxed
to a 0.014" wire, providing an ultra low proﬁle, highly ﬂexible drug-eluting coronary
stent system speciﬁcally designed for direct stenting. The DIRECT I First-In-Man
study (Webster, Ormiston et al., n¼30) reported 0% clinically-driven MACE at
12-months with 2.7% stent volume obstruction (via IVUS) and 98% strut coverage
(via OCT) observed at 6-months. All imaging was reviewed and adjudicated by
independent core lab and DSMB
Methods: The DIRECT II study is a prospective, randomized, active-control, multi-
center, non-inferiority study comparing the safety and efﬁcacy of the Svelte drug-
eluting coronary stent IDS to the Medtronic Vascular (Santa Rosa, CA) Resolute
IntegrityTM DES. 159 patients (2:1 randomization Svelte IDS : Resolute IntegrityTM)
were treated with angiographic follow-up scheduled at 6-months to assess the primary
endpoints of TVF and LL. Patients with symptomatic ischemic heart disease due to de
novo stenotic lesions in arteries with RVD 2.5mm – 3.5mm and lesion length < 20
mm were included. Stent evaluation post-procedure and at 6-month follow-up in
30 patients was also performed at sites with OCT capability. Additional clinical
follow-up will take place through 5-years for all patients. Enrolment began January
2013 and will complete August 2013.
Results: Procedural and 30-day data on all patients, alongwith OCT image analysis, will
be presented. Comparative data for time and cost savings, including overall procedural
time, adjunctive product use, contrast use and radiation exposure, will be reported.
Conclusions: A review of the Svelte DES platform and available procedural and 30-
day results from the study will be provided. These data provide insights into the
potential procedural and clinical beneﬁts, as well as time and cost savings, of this
unique drug-eluting stent system.
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Background: The Svelte (New Providence, NJ) drug-eluting stent combines sirolimus
with a novel, amino acid-based fully bioabsorbable drug carrier. The stent is mounted
on an Integrated Delivery System (IDS) consisting of a low compliant balloon with
balloon control bands enveloping the balloon edges and afﬁxed to a 0.014" wire,
providing a very low proﬁle, ﬂexible, drug-eluting coronary stent system speciﬁcally
designed for direct stenting. The DIRECT I ﬁrst-in-man study was designed to
evaluate the feasibility of the Svelte drug-eluting stent IDS.
Methods: 30 patients with a de novo lesion in a native coronary artery, with a reference
vessel diameter between 2.5 mm and 3.5 mm and lesion length < 23 mm, were
assessed. Patients with successful, uncomplicated treatment of one additional lesion in
a non-target vessel were also included. All patients completed 6-month QCA and IVUS
(+ OCT in a subset) and are followed clinically for 5-years. The study primary endpoints
were target vessel failure and angiographic late lumen loss at 6-months.
Results: At 6 months, no patient had suffered a clinically-driven MACE, there was
2.7% stent volume obstruction (via IVUS) and stent strut coverage was 98% (via
OCT). There were no adverse clinical results between 6 and 12 months, indicating no
evidence of late catch-up. Full independent core lab and DSMB-adjudicated baseline
and 6 month QCA, IVUS and OCT data, and clinical outcomes to 12-months will be
reported.
Conclusions: The Svelte sirolimus-eluting coronary stent IDS, utilizing an anti-
inﬂammatory, naturally-occurring amino acid-based drug carrier, demonstrated
excellent clinical outcomes, low neointimal proliferation, and uniform vessel healing
at 6-months. The clinical beneﬁt was sustained in all patients through 12-months.
DIRECT II, a prospective, randomized, active-control, multi-center, non-inferiority
study is currently underway.B64 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-198
Six Years Consecutive Complete Follow-up Result of Sirolimus Eluting Stent
(SES) Implanted Lesion.
Yohei Inoue1, Yoshisato Shibata2
1Miyazaki Medical Association Hospital, Miyazaki City, Miyazaki Prefecture,
2Miyazaki medical association hospital, Miyazaki, Japan
Background: In many reports, SES is more effective in decreasing late lumen loss
and restenosis rate than BMS. However, long-term follow-up results of SES remain
unclear. We sometimes experience late restenosis cases in SES implanted lesion.
Methods: We tried angiographic follow-up every year of the patients SES implanted.
We could follow 60 lesions completely and evaluated MLD of those lesions in each
year. We ruled out revascularised lesions. We sometimes experience late restenosis
cases in SES implanted lesion.
Results: We implanted SES in 3972 lesions in the heart center from April 2004 to
August 2012. We studied consecutive 58 lesions we could follow up every year. We
estimated the changes of MLD of these 58 lesions. During 1 to 2-year follow-up, there
is not remarkable change in MLD (1-year: 2.620.55, 2-year: 2.490.56). But at
3-year follow-up, MLD got smaller remarkably (3-year:2.290.65). After that there is
not remarkable change (4-year: 2.300.70, 5-year:2.260.74, 6-year:2.210.58).
7.4% of 3-year follow-up patients, 5.5% of 4-year follow-up patients and 7.5% of
5-year follow-up patients are ruled out by revascularization.Conclusions: MLD of SES implanted lesions get smaller. The extent of lumen loss
was large after 3 years of PCI. We have to follow up SES implanted patients carefully
and continuously because of late stent thrombosis and late restenosis. But this result
suggest that late restenosis becomes less common in 4 years or later after SES
implanted.TCT-199
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Background: A novel sirolimus-eluting stent with a bioabsorbable polymer (Osiro,
Biotronik, Germany) is now available. The safety and efﬁcacy of this drug-eluting
stent (DES) in an all comers setting is unknown.
Methods: Between June 2011 and January 2013, 234 patients were treated with the
Osiro (Biotronik, Germany) stent. Indication for the Osiro (Biotronik, Germany) was
left to the operator discretion. Demographic, clinical and procedural characteristics
were collected through institutional and catheterization databases review. Short and
long-term clinical follow-up were available through institutional database review and
telephone contact.
Results: The mean age was 6510 years with a predominance of male (76%). They
had hypertension in 70% and diabetes in 35% of cases. Coronary artery disease was
already known in most patients as 47% had a previous percutaneous coronary
intervention 40% had a myocardial infarction (MI) and 18% had previous coronary
artery bypass surgery. Clinical presentation was acute coronary syndrome in 77% of
patients. Mean reference diameter was 2.80.5mm, lesion length was 2215 mm
and lesion stenosis was 8013%. The mean used stent diameter and length were
2.80.4mm and 226mm respectively. Osiro stent was used to treat bifurcation
lesion in 34% and thrombus-containing lesion in 11%. Procedural and technicalj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
